8-K: Astrana Health Reports Strong Q2 2026 Results, Raises Guidance

Astrana Health announced robust second quarter 2026 financial results, showcasing significant year-over-year growth in revenue, net income, and adjusted EBITDA, and raised its full-year adjusted EBITDA guidance.

Summary

• Astrana Health reported strong financial results for the second quarter ended June 30, 2026.
• Total revenue for the quarter was $972.5 million, a 49% increase year-over-year.
• Net income attributable to Astrana was $19.7 million, an increase of 109% year-over-year.
• Adjusted EBITDA for the quarter was $68.9 million, up 43% year-over-year.
• For the first six months of 2026, total revenue reached $1,937.6 million, a 52% increase year-over-year.
• Net cash provided by operating activities for the six months was $100.8 million, and free cash flow was $92.9 million.
• The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $255 million to $280 million.
• Revenue from Care Partners was $932.8 million, up 48% year-over-year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong year-over-year growth in revenue and net income, alongside increased guidance for Adjusted EBITDA.

Positives

• Significant year-over-year revenue growth of 49% in Q2 2026, reaching $972.5 million.
• Net income attributable to Astrana Health more than doubled, increasing by 109% to $19.7 million.
• Adjusted EBITDA grew by 43% year-over-year to $68.9 million, demonstrating strong operational profitability.
• Diluted EPS increased by 111% to $0.40.
• Strong performance in the first six months of 2026 with revenue up 52% to $1,937.6 million and Adjusted EBITDA up 60% to $135.2 million.
• Robust free cash flow generation of $92.9 million for the first six months of 2026.
• Raised full-year 2026 Adjusted EBITDA guidance to $255-$280 million, reflecting confidence in continued growth.
• Affiliated ACOs generated $120.4 million in gross shared savings for the 2024 performance year.

Negatives

• While not explicitly negative, the company is reinvesting a substantial portion of its first-half outperformance into growth opportunities, which may impact short-term profitability.
• The company's consolidated balance sheet shows a decrease in cash and cash equivalents from $429.5 million at the end of 2025 to $400.8 million at the end of Q2 2026.
• Long-term debt remains substantial at $882.7 million as of June 30, 2026.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those described in its SEC filings, which could cause actual results to differ materially.
• The company has a material weakness in internal control over financial reporting and its ability to remediate this weakness in a timely manner is a risk.
• The company's business is subject to the evolving healthcare landscape, including regulatory changes and competitive pressures.
• Reliance on third-party service providers for data and statistics introduces potential risks if such information is inaccurate or incomplete.

Future Outlook

Astrana Health is providing guidance for the third quarter of 2026 with total revenue projected between $1,000 million and $1,030 million, and Adjusted EBITDA between $72.5 million and $77.5 million. For the full year 2026, the company is updating its Adjusted EBITDA guidance to a range of $255 million to $280 million and reaffirming its revenue and free cash flow guidance.

Management Comments

• "Our second quarter results reflect the strength of Astrana's physician-centric, AI-native healthcare operating system and the disciplined execution of our team," said Brandon Sim, President and Chief Executive Officer of Astrana Health.
• "We continue to see accelerating demand from both providers and payers for our platform, driving strong growth, record-high adjusted diluted EPS, and robust free cash flow generation."
• "Our performance gives us the confidence to raise our adjusted EBITDA guidance for 2026 even as we reinvest a substantial portion of our first-half outperformance into attractive growth opportunities that we believe will further strengthen our earnings power over time."

Industry Context

StockSavvy.ai notes that Astrana Health's performance aligns with the broader trend in the healthcare industry towards value-based care models, driven by technology and AI to improve efficiency and patient outcomes. The company's focus on a physician-centric approach and its expansion in Medicare Advantage are key strategies in this evolving market.

Comparison to Industry Standards

• Astrana Care Partners ACO ranked seventh nationwide in net shared savings per beneficiary in its first performance year (2024).
• The company's revenue growth of 49% in Q2 2026 significantly outpaces the growth rates of many traditional healthcare providers and payers.
• The shift towards full-risk arrangements (81% of Q2 2026 capitation revenue) indicates a strategic alignment with industry best practices for value-based care, aiming to capture more shared savings and manage costs effectively.

Legal Proceedings

• Accruals for non-routine legal matters were noted in the 'Other, net' adjustments for Q2 2026.

Related Party Transactions

• Receivables, net, include amounts from related parties.
• Investment in other entities equity method.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and potential for future earnings growth.
• Providers: Continued demand for Astrana's platform suggests ongoing partnership opportunities and potential for shared savings.
• Payers: Expansion of Medicare Advantage footprint and focus on value-based care indicate efforts to align with payer goals for cost containment and quality improvement.
• Employees: The addition of new executives suggests a focus on strengthening leadership for scaling operations.

Next Steps

• Continue to reinvest outperformance into growth opportunities.
• Further develop and deploy proprietary AI-enabled tools.
• Expand Medicare Advantage footprint.
• Continue prudent shift toward full-risk, accountable care contracts.

Key Dates

Recommendation

The strong Q2 2026 results, marked by significant year-over-year growth in revenue, net income, and adjusted EBITDA, coupled with an increase in full-year guidance, indicate robust operational execution and positive market reception. The company's strategic focus on AI-native, physician-centric value-based care positions it well for continued expansion and profitability in the evolving healthcare landscape.

Keywords

Healthcare Technology, Value-Based Care, Physician-Centric, AI-Native, Managed Care, Accountable Care Organizations, Medicare Advantage, Financial Results